Symbols / OMER $10.90 -9.77% Omeros Corporation

Healthcare • Biotechnology • United States • NGM
OMER Chart
About

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 772.81M
Enterprise Value 862.79M Income -4.81M Sales —
Book/sh -1.69 Cash/sh 2.39 Dividend Yield —
Payout 0.00% Employees 175 IPO —
P/E — Forward P/E 7.92 PEG —
P/S — P/B -6.45 P/C —
EV/EBITDA -7.08 EV/Sales — Quick Ratio 2.34
Current Ratio 2.76 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.08 EPS next Y 1.38 EPS Growth —
Revenue Growth — Earnings 2026-05-14 ROA -25.47%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 70.90M
Shs Float 69.24M Short Float 25.34% Short Ratio 20.56
Short Interest — 52W High 17.65 52W Low 2.95
Beta 2.53 Avg Volume 1.42M Volume 1.84M
Target Price $38.00 Recom Buy Prev Close $12.08
Price $10.90 Change -9.77%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.00
Mean price target
2. Current target
$10.90
Latest analyst target
3. DCF / Fair value
$43.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.90
Low
$36.00
High
$40.00
Mean
$38.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-27 main D. Boral Capital Buy → Buy $36
2026-01-08 main HC Wainwright & Co. Buy → Buy $40
2026-01-08 main D. Boral Capital Buy → Buy $36
2025-12-24 main D. Boral Capital Buy → Buy $36
2025-12-01 main D. Boral Capital Buy → Buy $36
2025-11-14 main D. Boral Capital Buy → Buy $36
2025-10-16 main D. Boral Capital Buy → Buy $36
2025-10-15 reit Needham Hold → Hold —
2025-10-15 reit WBB Securities Strong Buy → Strong Buy $45
2025-10-15 main HC Wainwright & Co. Buy → Buy $20
2025-10-15 main D. Boral Capital Buy → Buy $36
2025-09-03 main D. Boral Capital Buy → Buy $36
2025-08-15 main D. Boral Capital Buy → Buy $36
2025-08-15 reit Needham Hold → Hold —
2025-07-25 main D. Boral Capital Buy → Buy $36
2025-06-30 main D. Boral Capital Buy → Buy $36
2025-06-10 init HC Wainwright & Co. — → Buy $9
2025-05-16 reit Needham Hold → Hold —
2025-05-13 main D. Boral Capital Buy → Buy $36
2025-05-07 main D. Boral Capital Buy → Buy $36
News
RSS: Latest OMER news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 DEMOPULOS GREGORY A. M.D. Chief Executive Officer — 400,000 $10.27 $4,108,000
2026-01-13 BORGES DAVID J. Officer — 30,000 $3.06 $91,800
2026-01-13 BORGES DAVID J. Officer — 60,000 $12.31 $750,915
2025-10-13 DEMOPULOS GREGORY A. M.D. Chief Executive Officer — 600,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Cost Of Revenue
—
—
—
—
Reconciled Cost Of Revenue
—
—
—
—
Gross Profit
—
—
—
—
Operating Expense
122.80
-26.45%
166.95
+1.47%
164.53
+0.70%
163.39
Research And Development
81.30
-31.98%
119.52
+4.05%
114.87
+1.91%
112.72
Selling General And Administration
41.50
-12.50%
47.43
-4.49%
49.66
-1.99%
50.67
General And Administrative Expense
41.50
-12.50%
47.43
-4.49%
49.66
-1.99%
50.67
Salaries And Wages
4.66
-26.70%
6.36
-10.92%
7.14
-11.22%
8.04
Other Gand A
36.84
-10.30%
41.07
-3.41%
42.52
-0.25%
42.63
Total Expenses
122.80
-26.45%
166.95
+1.47%
164.53
+0.70%
163.39
Operating Income
-122.80
+26.45%
-166.95
-1.47%
-164.53
-0.70%
-163.39
Total Operating Income As Reported
-122.80
+26.45%
-166.95
-1.47%
-164.53
-0.70%
-163.39
EBITDA
-121.83
+21.25%
-154.70
-8.06%
-143.16
+9.61%
-158.38
Normalized EBITDA
-236.78
-53.04%
-154.72
-5.06%
-147.27
+7.01%
-158.38
Reconciled Depreciation
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
EBIT
-122.80
+21.11%
-155.65
-8.03%
-144.08
+9.57%
-159.33
Total Unusual Items
114.94
+604868.42%
0.02
-99.54%
4.11
0.00
Total Unusual Items Excluding Goodwill
114.94
+604868.42%
0.02
-99.54%
4.11
0.00
Special Income Charges
251.66
0.00
-100.00%
4.11
0.00
Other Special Charges
-14.07
—
-4.11
—
Net Income
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Pretax Income
-2.80
+98.45%
-180.32
-3.09%
-174.92
+3.91%
-182.03
Net Non Operating Interest Income Expense
5.06
+137.76%
-13.39
+7.67%
-14.50
+22.20%
-18.64
Interest Expense Non Operating
—
24.68
-20.00%
30.84
+35.86%
22.70
Net Interest Income
5.06
+137.76%
-13.39
+7.67%
-14.50
+22.20%
-18.64
Interest Expense
—
24.68
-20.00%
30.84
+35.86%
22.70
Interest Income Non Operating
5.06
-55.20%
11.29
-30.94%
16.34
+302.31%
4.06
Interest Income
5.06
-55.20%
11.29
-30.94%
16.34
+302.31%
4.06
Other Income Expense
114.94
+604868.42%
0.02
-99.54%
4.11
—
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
-136.72
-719663.16%
0.02
—
—
Gain On Sale Of Business
237.59
—
—
—
Tax Provision
2.01
-12.71%
2.31
0.00
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
24.14
+604868.42%
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Net Income From Continuing Operation Net Minority Interest
-4.81
+97.37%
-182.63
-4.41%
-174.92
+3.91%
-182.03
Net Income From Continuing And Discontinued Operation
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Net Income Continuous Operations
-4.81
+97.37%
-182.63
-4.41%
-174.92
+3.91%
-182.03
Net Income Discontinuous Operations
1.46
-94.35%
25.81
-54.80%
57.11
-75.11%
229.45
Normalized Income
-95.61
+47.65%
-182.64
-2.02%
-179.03
+1.65%
-182.03
Net Income Common Stockholders
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Diluted EPS
-0.05
+98.15%
-2.70
-43.62%
-1.88
-347.37%
0.76
Basic EPS
-0.05
+98.15%
-2.70
-43.62%
-1.88
-347.37%
0.76
Basic Average Shares
63.51
+9.18%
58.17
-7.28%
62.74
+0.00%
62.74
Diluted Average Shares
63.51
+9.18%
58.17
-7.28%
62.74
+0.00%
62.74
Diluted NI Availto Com Stockholders
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
325.63
+17.52%
277.08
-26.75%
378.27
-35.99%
590.97
Current Assets
215.67
+60.80%
134.12
-38.45%
217.90
-50.84%
443.24
Cash Cash Equivalents And Short Term Investments
171.80
+90.61%
90.13
-47.55%
171.85
-11.84%
194.92
Cash And Cash Equivalents
9.66
+184.12%
3.40
-52.15%
7.11
-35.46%
11.01
Other Short Term Investments
162.14
+86.95%
86.73
-47.35%
164.74
-10.42%
183.91
Receivables
36.27
-1.50%
36.82
-1.73%
37.47
-84.52%
242.02
Accounts Receivable
6.44
-7.16%
6.94
+3.21%
6.72
-96.84%
212.97
Other Receivables
29.82
-0.19%
29.88
-2.81%
30.75
+5.83%
29.05
Prepaid Assets
—
—
—
—
Other Current Assets
7.59
+5.99%
7.17
-16.49%
8.58
+36.21%
6.30
Total Non Current Assets
109.97
-23.08%
142.96
-10.86%
160.37
+8.55%
147.73
Net PPE
12.48
-29.27%
17.64
-14.29%
20.58
-11.49%
23.25
Gross PPE
24.51
-14.63%
28.71
-6.85%
30.82
-6.04%
32.80
Accumulated Depreciation
-12.04
-8.71%
-11.07
-8.11%
-10.24
-7.26%
-9.55
Properties
—
0.00
0.00
0.00
Buildings And Improvements
—
14.96
-19.70%
18.63
-14.39%
21.76
Machinery Furniture Equipment
1.74
+0.00%
1.74
+0.00%
1.74
+2.12%
1.70
Other Properties
22.77
-15.57%
26.97
-7.26%
29.09
-6.48%
31.10
Non Current Accounts Receivable
96.44
-22.40%
124.27
-10.43%
138.74
+12.41%
123.42
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
1.05
+0.00%
1.05
+0.00%
1.05
+0.00%
1.05
Total Liabilities Net Minority Interest
446.86
-2.79%
459.69
+14.00%
403.25
-20.19%
505.29
Current Liabilities
78.06
-1.84%
79.53
+49.16%
53.32
-60.91%
136.38
Payables And Accrued Expenses
21.33
-6.68%
22.86
-29.01%
32.20
+7.78%
29.88
Payables
5.91
-0.84%
5.96
-22.72%
7.71
+28.77%
5.99
Accounts Payable
4.76
-19.32%
5.91
-23.43%
7.71
+28.77%
5.99
Current Accrued Expenses
15.42
-8.75%
16.90
-30.99%
24.49
+2.52%
23.89
Pensionand Other Post Retirement Benefit Plans Current
10.35
+16.69%
8.87
+20.16%
7.38
+10.73%
6.67
Total Tax Payable
1.15
+1983.64%
0.06
—
4.87
Income Tax Payable
1.15
+1983.64%
0.06
—
4.87
Current Debt And Capital Lease Obligation
23.36
-13.38%
26.97
+422.69%
5.16
-94.77%
98.69
Current Debt
17.06
-18.75%
21.00
—
94.38
Other Current Borrowings
17.06
-18.75%
21.00
—
94.38
Current Capital Lease Obligation
6.30
+5.51%
5.97
+15.72%
5.16
+19.72%
4.31
Current Deferred Liabilities
2.47
+1251.37%
0.18
—
—
Current Deferred Revenue
2.47
+1251.37%
0.18
—
—
Other Current Liabilities
20.55
-0.47%
20.64
+140.73%
8.58
+644.44%
1.15
Total Non Current Liabilities Net Minority Interest
368.80
-2.99%
380.16
+8.64%
349.94
-5.14%
368.90
Long Term Debt And Capital Lease Obligation
215.78
+19.85%
180.05
-22.16%
231.30
-4.95%
243.33
Long Term Debt
208.53
+25.18%
166.58
-21.85%
213.16
-3.51%
220.91
Long Term Capital Lease Obligation
7.25
-46.20%
13.47
-25.78%
18.14
-19.10%
22.43
Other Non Current Liabilities
147.32
-24.69%
195.61
+67.84%
116.55
-6.85%
125.13
Stockholders Equity
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Common Stock Equity
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Capital Stock
0.72
+23.45%
0.58
-5.07%
0.61
-2.71%
0.63
Common Stock
0.72
+23.45%
0.58
-5.07%
0.61
-2.71%
0.63
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
71.67
+23.48%
58.04
-5.05%
61.13
-2.71%
62.83
Ordinary Shares Number
71.67
+23.48%
58.04
-5.05%
61.13
-2.71%
62.83
Additional Paid In Capital
791.75
+8.88%
727.16
-0.11%
727.94
+0.99%
720.77
Retained Earnings
-913.70
-0.37%
-910.35
-20.81%
-753.53
-18.53%
-635.72
Total Equity Gross Minority Interest
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Total Capitalization
87.30
+644.76%
-16.03
-108.52%
188.17
-38.62%
306.59
Working Capital
137.60
+152.05%
54.59
-66.83%
164.58
-46.36%
306.85
Invested Capital
104.37
+1998.25%
4.97
-97.36%
188.17
-53.07%
400.97
Total Debt
239.14
+15.52%
207.02
-12.45%
236.46
-30.86%
342.02
Net Debt
215.94
+17.24%
184.18
-10.61%
206.05
-32.28%
304.28
Capital Lease Obligations
13.54
-30.31%
19.44
-16.59%
23.30
-12.84%
26.74
Net Tangible Assets
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Tangible Book Value
-121.23
+33.61%
-182.61
-630.93%
-24.98
-129.16%
85.68
Interest Payable
0.62
-76.90%
2.67
-37.13%
4.24
-17.98%
5.17
Non Current Accrued Expenses
5.70
+26.68%
4.50
+115.57%
2.09
+370.27%
0.44
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-116.09
+21.98%
-148.80
-299.13%
74.73
+186.41%
-86.48
Cash Flow From Continuing Operating Activities
-116.09
+21.98%
-148.80
-299.13%
74.73
+186.41%
-86.48
Net Income From Continuing Operations
-3.35
+97.86%
-156.81
-33.11%
-117.81
-348.46%
47.42
Depreciation Amortization Depletion
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
Depreciation And Amortization
0.96
+1.47%
0.95
+3.26%
0.92
-3.36%
0.95
Other Non Cash Items
-37.13
-8.16%
-34.33
+37.16%
-54.63
-84.77%
-29.57
Stock Based Compensation
8.19
-21.93%
10.49
-9.93%
11.65
-17.21%
14.07
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
-255.21
—
-4.11
—
Unrealized Gain Loss On Investment Securities
136.72
+719663.16%
-0.02
0.00
—
Change In Working Capital
33.72
-4.45%
35.29
-85.74%
247.42
+307.30%
-119.36
Change In Receivables
30.45
-23.90%
40.01
-83.72%
245.72
+324.14%
-109.63
Changes In Account Receivables
-3.18
-990.20%
0.36
-99.83%
205.12
+217.17%
-175.07
Change In Prepaid Assets
-1.31
-353.58%
0.52
+117.36%
-2.98
-418.84%
0.93
Change In Payables And Accrued Expense
4.58
+187.46%
-5.24
-211.90%
4.68
+143.90%
-10.66
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
—
—
—
—
Investing Cash Flow
164.52
+100.11%
82.22
+199.47%
27.45
+121.52%
-127.56
Cash Flow From Continuing Investing Activities
164.52
+100.11%
82.22
+199.47%
27.45
+121.52%
-127.56
Net PPE Purchase And Sale
239.94
+145515.15%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Purchase Of PPE
-0.07
+60.61%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Sale Of PPE
240.00
0.00
0.00
—
Capital Expenditure
-0.07
+60.61%
-0.17
+61.27%
-0.43
-276.99%
-0.11
Net Investment Purchase And Sale
-75.41
-191.54%
82.38
+195.49%
27.88
+121.88%
-127.45
Purchase Of Investment
-185.31
+81.23%
-987.38
+3.06%
-1,018.60
-137.41%
-429.05
Sale Of Investment
109.90
-89.73%
1,069.77
+2.23%
1,046.48
+246.98%
301.59
Net Business Purchase And Sale
—
—
0.00
0.00
Gain Loss On Sale Of Business
-237.59
0.00
0.00
0.00
Financing Cash Flow
-42.17
-167.06%
62.88
+159.27%
-106.08
-185.38%
124.25
Cash Flow From Continuing Financing Activities
-42.17
-167.06%
62.88
+159.27%
-106.08
-185.38%
124.25
Net Issuance Payments Of Debt
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Net Long Term Debt Issuance
-89.16
-115.68%
-41.34
+59.30%
-101.58
-8604.37%
-1.17
Net Common Stock Issuance
39.34
+431.98%
-11.85
-154.64%
-4.65
0.00
Common Stock Payments
0.00
+100.00%
-11.85
-154.64%
-4.65
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-11.85
-154.64%
-4.65
0.00
Proceeds From Stock Option Exercised
7.65
+1298.72%
0.55
+264.67%
0.15
-63.86%
0.41
Net Other Financing Charges
—
115.53
—
125.00
Changes In Cash
6.26
+268.96%
-3.71
+5.10%
-3.90
+95.65%
-89.80
Beginning Cash Position
3.40
-52.15%
7.11
-35.46%
11.01
-89.08%
100.81
End Cash Position
9.66
+184.12%
3.40
-52.15%
7.11
-35.46%
11.01
Free Cash Flow
-116.16
+22.02%
-148.97
-300.50%
74.30
+185.80%
-86.60
Interest Paid Supplemental Data
35.42
-0.75%
35.69
+19.26%
29.92
+56.03%
19.18
Income Tax Paid Supplemental Data
0.15
-7.27%
0.17
-94.99%
3.29
+4015.00%
0.08
Amortization Of Securities
0.00
+100.00%
-4.37
+49.84%
-8.71
0.00
Common Stock Issuance
39.34
0.00
0.00
0.00
Issuance Of Capital Stock
39.34
0.00
0.00
0.00
Sale Of Business
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category